| Track 1: New Technology of Drug Delivery Systems |
| Track 1-1: |
Sustained, Controlled or Modified-release Drug Delivery |
| Track 1-2: |
Prodrugs for Better Efficacy |
| Track 1-3: |
Electronically Controlled Drug Delivery Sysytems |
| Track 1-4: |
Biocompatible Polymers and Biopolymers |
| Track 1-5: |
Formulation and Drug Delivery Development of Poorly Soluble Drugs |
| Track 1-6: |
Gene and Cell Therapy |
| Track 2: Development of Personalized Medicine |
| Track 3: Biopharmaceuticals Development |
| Track 3-1: |
Biopharmaceutics and Formulation Development |
| Track 3-2: |
Role of PK/PD in Product Development |
| Track 3-3: |
Drug Development of Pediatrics: Formulation and Regulatory Aspects |
| Track 3-4: |
Bioavailability and Bioequivalence in Disease State |
| Track 4: Identification and Characterization of Drugs |
| Track 4-1: |
Characterization of Synthetic and Natural Products |
| Track 4-2: |
Structural Analysis: Characterization of Process or Product Related Impurities
and Degradants |
| Track 4-3: |
Instrumental Methods for Identification and Characterization |
| Track 4-4: |
Metabolite Characterization: Drug Discovery |
| Track 4-5: |
Advanced Techniques in Structure Characterization |
| Track 5: Quality Management System in Pharmaceutical Industry |
| Track 5-1: |
Pharmaceutical Development & Quality Systems |
| Track 5-2: |
Quality Assurance and Quality Control for Pharmaceutical Development |
| Track 5-3: |
Quality Assessment for Pharmaceutical Products |
| Track 5-4: |
Food and Drug Safety |
| Track 5-5: |
Quality by Design: Broadening the Application and Sharing the Learnings |
| Track 6: Pharmacokinetic Considerations of Drug Delivery |
| Track 6-1: |
Pharmacokinetic Parameters for Drug Disposotion |
| Track 6-2: |
Pharmacokinetic Parameters for Drug Input |
| Track 6-3: |
Pharmacokinetic model for presystemic metabolism |
| Track 6-4: |
BA/BE studies of Pharmacokinetic Drug Interactions |
| Track 7: Trends in Drug Delivery Systems of Global Market |
| Track 7-1: |
Global Needs and Strategies for Novel Dosage Forms |
| Track 7-2: |
Generic Development of Drug Delivery Systems |
| Track 7-3: |
Product Planning, Technology Evaluation and Product/Brand Management |
| Track 7-4: |
Successful Drug Discovery from the Research Lab to the Marketplace |
| Track 8: Novel Drug Delivery System Technology Targeting Different
Route of Administration |
| Track 8-1: |
Oral, Transmuco Adhesive and Buccal Drug Delivery |
| Track 8-2: |
Rectal and Vaginal Drug Delivery |
| Track 8-3: |
Nasal and Inhalable Drug Delivery |
| Track 8-4: |
Transdermal and Topical Drug Delivery |
| Track 8-5: |
Ocular Drug Delivery |
| Track 8-6: |
Novel Approaches in Drug Delivery |
| Track 9: Nanotech for Drug Delivery |
| Track 9-1: |
Biocompatible and Biodegradable Materials for Drug Nanoparticles |
| Track 9-2: |
Controlled Delivery of Nanoparticles in DDS |
| Track 9-3: |
Nanoparticles as Drug Carrier in DDS |
| Track 9-4: |
Site-Directed Controlled Nano-drug Delivery Systems |
| Track 10: Regulatory Issues, Quality Control, and Business Development |
| Track 10-1: |
Clinical Trials in Emerging Markets |
| Track 10-2: |
Benefit/Risk Assessment during Drug Development |
| Track 10-3: |
Safety and Quality Regulation |
| Track 10-4: |
Pharmacovigilance and Safety management |
| Track 10-5: |
Regulatory challenges in Nano and Biotech Therapeutics |